Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

ABUS – Arbutus Biopharma Corporation

Arbutus Biopharma Corporation
ABUS
$3.42
Name : Arbutus Biopharma Corporation
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $648,062,656.00
EPSttm : -0.43
finviz dynamic chart for ABUS
Arbutus Biopharma Corporation
$3.42
0.58%
$0.02

Float Short %

4.56

Margin Of Safety %

Put/Call OI Ratio

0.52

EPS Next Q Diff

-0.03

EPS Last/This Y

EPS This/Next Y

0.07

Price

3.42

Target Price

5.2

Analyst Recom

1.4

Performance Q

-2.84

Relative Volume

1.24

Beta

1.94

Ticker: ABUS




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-01-23ABUS3.350.540.0112442
2025-01-24ABUS3.330.530.0012633
2025-01-27ABUS3.430.530.0012688
2025-01-28ABUS3.350.511.0012957
2025-01-29ABUS3.380.560.0014958
2025-01-30ABUS3.30.560.0015034
2025-01-31ABUS3.340.550.0015148
2025-02-03ABUS3.280.540.1515289
2025-02-04ABUS3.360.540.0015299
2025-02-05ABUS3.60.540.0015398
2025-02-06ABUS3.410.520.0115717
2025-02-07ABUS3.440.500.0216146
2025-02-10ABUS3.340.500.0016150
2025-02-11ABUS3.310.500.0216174
2025-02-12ABUS3.320.500.0016201
2025-02-13ABUS3.30.490.0316257
2025-02-14ABUS3.290.490.0016338
2025-02-18ABUS3.360.490.0016384
2025-02-19ABUS3.390.490.2916447
2025-02-20ABUS3.440.480.0916534
2025-02-21ABUS3.420.520.0116571
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-01-23ABUS3.3429.0- -0.54
2025-01-24ABUS3.3229.0- -0.54
2025-01-27ABUS3.4329.0- -0.54
2025-01-28ABUS3.3529.0- -0.54
2025-01-29ABUS3.3729.0- -0.54
2025-01-30ABUS3.3029.0- -0.54
2025-01-31ABUS3.3429.0- -0.54
2025-02-03ABUS3.2829.0- -0.54
2025-02-04ABUS3.3529.0- -0.54
2025-02-05ABUS3.5929.0- -0.54
2025-02-06ABUS3.4129.0- -0.54
2025-02-07ABUS3.4429.0- -0.54
2025-02-10ABUS3.3329.0- -0.54
2025-02-11ABUS3.3129.0- -0.54
2025-02-12ABUS3.3229.0- -0.54
2025-02-13ABUS3.3129.0- -0.54
2025-02-14ABUS3.2929.0- -0.54
2025-02-18ABUS3.3529.0- -0.54
2025-02-19ABUS3.3929.0- -0.54
2025-02-20ABUS3.4429.0- -0.54
2025-02-21ABUS3.4229.0- -0.54
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-01-23ABUS-0.025.544.04
2025-01-24ABUS-0.025.544.04
2025-01-27ABUS-0.024.494.04
2025-01-28ABUS-0.024.494.50
2025-01-29ABUS-0.024.494.50
2025-01-30ABUS-0.024.494.50
2025-01-31ABUS-0.024.494.50
2025-02-03ABUS-0.024.454.50
2025-02-04ABUS-0.024.454.50
2025-02-05ABUS-0.024.454.50
2025-02-06ABUS-0.204.454.50
2025-02-07ABUS-0.204.454.50
2025-02-10ABUS-0.203.884.52
2025-02-11ABUS-0.203.884.52
2025-02-12ABUS-0.203.884.57
2025-02-13ABUS-0.203.884.56
2025-02-14ABUS-0.203.884.56
2025-02-18ABUS-0.183.774.56
2025-02-19ABUS-0.183.774.56
2025-02-20ABUS-0.183.774.56
2025-02-21ABUS-0.183.774.56
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.09

Avg. EPS Est. Current Quarter

-0.12

Avg. EPS Est. Next Quarter

-0.12

Insider Transactions

-0.18

Institutional Transactions

3.77

Beta

1.94

Average Sales Estimate Current Quarter

2

Average Sales Estimate Next Quarter

1

Fair Value

Quality Score

26

Growth Score

28

Sentiment Score

96

Actual DrawDown %

62.1

Max Drawdown 5-Year %

-73.3

Target Price

5.2

P/E

Forward P/E

PEG

P/S

96.15

P/B

6.06

P/Free Cash Flow

EPS

-0.43

Average EPS Est. Cur. Y​

-0.54

EPS Next Y. (Est.)

-0.47

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-1137.64

Relative Volume

1.24

Return on Equity vs Sector %

-91

Return on Equity vs Industry %

-75.4

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.01

EBIT Estimation

Arbutus Biopharma Corporation
Sector: Healthcare
Industry: Biotechnology
Employees: 73
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
stock quote shares ABUS – Arbutus Biopharma Corporation Stock Price stock today
news today ABUS – Arbutus Biopharma Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch ABUS – Arbutus Biopharma Corporation yahoo finance google finance
stock history ABUS – Arbutus Biopharma Corporation invest stock market
stock prices ABUS premarket after hours
ticker ABUS fair value insiders trading

ABUS – Arbutus Biopharma Corporation

Arbutus Biopharma Corporation
ABUS
$3.42
Name : Arbutus Biopharma Corporation
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $648,062,656.00
EPSttm : -0.43
finviz dynamic chart for ABUS
Arbutus Biopharma Corporation
$3.42
0.58%
$0.02

Float Short %

4.56

Margin Of Safety %

Put/Call OI Ratio

0.52

EPS Next Q Diff

-0.03

EPS Last/This Y

EPS This/Next Y

0.07

Price

3.42

Target Price

5.2

Analyst Recom

1.4

Performance Q

-2.84

Relative Volume

1.24

Beta

1.94

Ticker: ABUS




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-01-23ABUS3.350.540.0112442
2025-01-24ABUS3.330.530.0012633
2025-01-27ABUS3.430.530.0012688
2025-01-28ABUS3.350.511.0012957
2025-01-29ABUS3.380.560.0014958
2025-01-30ABUS3.30.560.0015034
2025-01-31ABUS3.340.550.0015148
2025-02-03ABUS3.280.540.1515289
2025-02-04ABUS3.360.540.0015299
2025-02-05ABUS3.60.540.0015398
2025-02-06ABUS3.410.520.0115717
2025-02-07ABUS3.440.500.0216146
2025-02-10ABUS3.340.500.0016150
2025-02-11ABUS3.310.500.0216174
2025-02-12ABUS3.320.500.0016201
2025-02-13ABUS3.30.490.0316257
2025-02-14ABUS3.290.490.0016338
2025-02-18ABUS3.360.490.0016384
2025-02-19ABUS3.390.490.2916447
2025-02-20ABUS3.440.480.0916534
2025-02-21ABUS3.420.520.0116571
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-01-23ABUS3.3429.0- -0.54
2025-01-24ABUS3.3229.0- -0.54
2025-01-27ABUS3.4329.0- -0.54
2025-01-28ABUS3.3529.0- -0.54
2025-01-29ABUS3.3729.0- -0.54
2025-01-30ABUS3.3029.0- -0.54
2025-01-31ABUS3.3429.0- -0.54
2025-02-03ABUS3.2829.0- -0.54
2025-02-04ABUS3.3529.0- -0.54
2025-02-05ABUS3.5929.0- -0.54
2025-02-06ABUS3.4129.0- -0.54
2025-02-07ABUS3.4429.0- -0.54
2025-02-10ABUS3.3329.0- -0.54
2025-02-11ABUS3.3129.0- -0.54
2025-02-12ABUS3.3229.0- -0.54
2025-02-13ABUS3.3129.0- -0.54
2025-02-14ABUS3.2929.0- -0.54
2025-02-18ABUS3.3529.0- -0.54
2025-02-19ABUS3.3929.0- -0.54
2025-02-20ABUS3.4429.0- -0.54
2025-02-21ABUS3.4229.0- -0.54
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-01-23ABUS-0.025.544.04
2025-01-24ABUS-0.025.544.04
2025-01-27ABUS-0.024.494.04
2025-01-28ABUS-0.024.494.50
2025-01-29ABUS-0.024.494.50
2025-01-30ABUS-0.024.494.50
2025-01-31ABUS-0.024.494.50
2025-02-03ABUS-0.024.454.50
2025-02-04ABUS-0.024.454.50
2025-02-05ABUS-0.024.454.50
2025-02-06ABUS-0.204.454.50
2025-02-07ABUS-0.204.454.50
2025-02-10ABUS-0.203.884.52
2025-02-11ABUS-0.203.884.52
2025-02-12ABUS-0.203.884.57
2025-02-13ABUS-0.203.884.56
2025-02-14ABUS-0.203.884.56
2025-02-18ABUS-0.183.774.56
2025-02-19ABUS-0.183.774.56
2025-02-20ABUS-0.183.774.56
2025-02-21ABUS-0.183.774.56
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.09

Avg. EPS Est. Current Quarter

-0.12

Avg. EPS Est. Next Quarter

-0.12

Insider Transactions

-0.18

Institutional Transactions

3.77

Beta

1.94

Average Sales Estimate Current Quarter

2

Average Sales Estimate Next Quarter

1

Fair Value

Quality Score

26

Growth Score

28

Sentiment Score

96

Actual DrawDown %

62.1

Max Drawdown 5-Year %

-73.3

Target Price

5.2

P/E

Forward P/E

PEG

P/S

96.15

P/B

6.06

P/Free Cash Flow

EPS

-0.43

Average EPS Est. Cur. Y​

-0.54

EPS Next Y. (Est.)

-0.47

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-1137.64

Relative Volume

1.24

Return on Equity vs Sector %

-91

Return on Equity vs Industry %

-75.4

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.01

EBIT Estimation

Arbutus Biopharma Corporation
Sector: Healthcare
Industry: Biotechnology
Employees: 73
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
stock quote shares ABUS – Arbutus Biopharma Corporation Stock Price stock today
news today ABUS – Arbutus Biopharma Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch ABUS – Arbutus Biopharma Corporation yahoo finance google finance
stock history ABUS – Arbutus Biopharma Corporation invest stock market
stock prices ABUS premarket after hours
ticker ABUS fair value insiders trading